Straits Times Index
3,308.81 +5.62 (+0.17%) Nikkei
38,724.66 +488.59 (+1.28%) Hang Seng
18,481.93 -96.37 (-0.52%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
63,623.13 -555.73 (-0.87%) CMC Crypto 200
1,364.08 +51.45 (+3.92%)
NeuroSense Therapeutics Ltd. (NRSN)
After hours:
| Previous close | 1.3300 |
| Open | 1.3400 |
| Bid | 1.2300 x 100 |
| Ask | 1.3200 x 100 |
| Day's range | 1.2300 - 1.3400 |
| 52-week range | 0.4000 - 2.3300 |
| Volume | |
| Avg. volume | 296,138 |
| Market cap | 22.014M |
| Beta (5Y monthly) | 1.56 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
NeuroSense Announces First Quarter 2024 Business Update
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.
- PR Newswire
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases announced today a collaboration in Alzheimer's Disease (AD) drug development with Genetika+, a leader in precision medicine for psychiatry and neurology. The multi-phase collaboration, which will commence in NeuroSense's currently ongoing Phase 2 AD clinical trial, leverages Genetika+'s state-of-the-art technology that derives frontal cortex neurons from individ
- PR Newswire
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, announces the presentation of data from the Company's PARADIGM Phase 2b study of PrimeC during an Emerging Science session (equivalent to Late Breaker) at the American Academy of Neurology Annual Meeting, which validates the previously announced topline data. In addition to the positive clinical outcomes, the study also demonstrated a positive trend toward impa
